Stay ahead of CF progression, treat the cause early

With ORKAMBI®▼ (lumacaftor/ivacaftor) you can now treat cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene1

What are you looking for?

Information on cystic fibrosis-causing mutations

Information about ORKAMBI® phase III clinical trials

Information about KALYDECO® phase III clinical trials

References

1. ORKAMBI® Summary of Product Characteristics. February 2018. Vertex Pharmaceuticals (Europe) Limited.

 
Close

Close

To access the Healthcare Professionals' section you must verify your professional status using OneKey Web Authentication.

Press continue to use your existing OneKey account or register for a new OneKey user account.

Link to website terms and conditions